BELSOMRA Drug Patent Profile

When do Belsomra patents expire, and when can generic versions of Belsomra launch?

Belsomra is a drug marketed by Merck Sharp Dohme and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has seventy-five patent family members in thirty-six countries.

The generic ingredient in BELSOMRA is suvorexant. One supplier is listed for this compound. Additional details are available on the suvorexant profile page.

DrugPatentWatch^® Generic Entry Outlook for Belsomra

Belsomra was eligible for patent challenges on August 13, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 29, 2033. This may change due to patent challenges or generic licensing.

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

There is one tentative approval for the generic drug (suvorexant), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for BELSOMRA

International Patents:	75
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	35
Clinical Trials:	34
Patent Applications:	443
Drug Prices:	Drug price information for BELSOMRA
What excipients (inactive ingredients) are in BELSOMRA?	BELSOMRA excipients list
DailyMed Link:	BELSOMRA at DailyMed

See drug prices for BELSOMRA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for BELSOMRA

Constraining patent/regulatory exclusivity:

11,980,623

NDA:

204569

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for BELSOMRA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Massachusetts Institute of Technology	PHASE4
Massachusetts General Hospital	PHASE4
University of Maryland, Baltimore	Phase 2

See all BELSOMRA clinical trials

Pharmacology for BELSOMRA

Drug Class	Orexin Receptor Antagonist
Mechanism of Action	Cytochrome P450 3A Inhibitors Orexin Receptor Antagonists P-Glycoprotein Inhibitors

Paragraph IV (Patent) Challenges for BELSOMRA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BELSOMRA	Tablets	suvorexant	5 mg, 10 mg, 15 mg and 20 mg	204569	1	2024-03-04

US Patents and Regulatory Information for BELSOMRA

BELSOMRA is protected by three US patents.

This potential generic entry date is based on patent 11,980,623.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569-001	Aug 13, 2014		RX	Yes	No	7,951,797		Y	Y
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569-003	Aug 13, 2014		RX	Yes	No	7,951,797		Y	Y
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569-002	Aug 13, 2014		RX	Yes	No	7,951,797		Y	Y
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569-004	Aug 13, 2014		RX	Yes	Yes	10,098,892		Y
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569-003	Aug 13, 2014		RX	Yes	No	11,980,623		Y
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569-001	Aug 13, 2014		RX	Yes	No	10,098,892		Y
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569-001	Aug 13, 2014		RX	Yes	No	11,980,623		Y

International Patents for BELSOMRA

When does loss-of-exclusivity occur for BELSOMRA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

European Patent Office

Japan

Mexico

Russian Federation

South Korea

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering BELSOMRA around the world.

Country	Patent Number	Title	Estimated Expiration
Honduras	2009001067
Canada	2670892
Russian Federation	2019126797	СОСТАВЫ ТВЕРДЫХ ДОЗИРОВАННЫХ ЛЕКАРСТВЕННЫХ ФОРМ АНТАГОНИСТА ОРЕКСИНОВОГО РЕЦЕПТОРА (COMPOSITIONS OF SOLID DOSAGE FORMS OF OREXIN RECEPTOR ANTAGONIST)
Argentina	088881
Denmark	2089382
South Korea	101299426
Australia	2013267613

Belsomra: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Belsomra (suvorexant) is a dual orexin receptor antagonist developed by Merck & Co. for the treatment of insomnia. Its market performance is influenced by its efficacy, safety profile, competitive landscape, and patent exclusivity.

What is Belsomra's Mechanism of Action and Approved Indications?

Belsomra targets the orexin system, a wakefulness-promoting pathway in the brain. By blocking the binding of orexin neuropeptides to their receptors (OX1R and OX2R), Belsomra reduces the stimulation of wakefulness, thereby promoting sleep.

Belsomra is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. It is available in multiple dosage strengths: 5 mg, 10 mg, 15 mg, and 20 mg. Dosing is typically initiated at 10 mg taken once per night, with potential titration to higher doses based on individual response and tolerability.

What is Belsomra's Patent Exclusivity and Expiration Status?

Merck holds several patents protecting Belsomra. The primary composition of matter patent is U.S. Patent No. 7,314,890, which was granted on January 1, 2009. This patent provides exclusivity until January 1, 2027 [1].

Additional patents cover methods of use, formulations, and polymorphs of suvorexant. These patents can extend market exclusivity beyond the initial composition of matter patent. For example, U.S. Patent No. 9,205,041, covering certain polymorphs, has a listed expiration date of June 29, 2031 [1].

Merck also secured a 5-year New Chemical Entity (NCE) exclusivity from the U.S. Food and Drug Administration (FDA) upon Belsomra's approval in August 2014. This NCE exclusivity expired in August 2019.

The interplay of these patents and regulatory exclusivities determines the period of market protection for Belsomra from generic competition.

How has Belsomra performed financially since its launch?

Belsomra was launched in the United States in late 2014. Its financial performance has been characterized by gradual market penetration, influenced by its unique mechanism of action and competition from established sleep aids.

Year	Net Sales (USD Billions)
2015	0.11
2016	0.23
2017	0.41
2018	0.62
2019	0.75
2020	0.79
2021	0.74
2022	0.70
2023	0.65

Source: Merck & Co. Annual Reports and SEC Filings [2, 3, 4, 5, 6, 7, 8, 9, 10]

Sales peaked in 2020, reflecting its established presence in the market. Subsequent years have seen a slight decline, potentially due to market saturation, generic entry in other regions, or increased competition.

What is Belsomra's competitive landscape?

Belsomra competes in the insomnia market, which is characterized by several classes of drugs, including:

• Benzodiazepines: e.g., temazepam, estazolam. These are older, effective but carry risks of dependence and withdrawal.
• Non-benzodiazepine hypnotics (Z-drugs): e.g., zolpidem (Ambien), eszopiclone (Lunesta), zaleplon (Sonata). These are widely prescribed but also carry risks of dependence and next-day impairment.
• Melatonin receptor agonists: e.g., ramelteon (Rozerem). This targets the circadian rhythm pathway.
• Antidepressants with sedative properties: e.g., trazodone, doxepin. These are often used off-label for insomnia.
• Other orexin receptor antagonists: While Belsomra was the first in its class, other orexin antagonists have emerged, such as daridorexant (Dayvigo), approved in 2022.

Merck's marketing strategy for Belsomra has focused on its distinct mechanism of action, positioning it as an alternative for patients who may not respond well to or tolerate existing therapies, particularly due to its lower risk profile for certain side effects like rebound insomnia or dependence compared to benzodiazepines and Z-drugs. However, the emergence of other orexin antagonists presents direct competition.

What are the key market drivers and challenges for Belsomra?

Market Drivers:

• Unmet Need: Insomnia remains a prevalent condition, driving demand for effective treatments.
• Novel Mechanism of Action: Belsomra offers a different approach compared to GABA-ergic agents, appealing to patients and physicians seeking alternatives.
• Safety Profile: Belsomra's profile, with generally lower risks of dependence and withdrawal compared to older hypnotics, is a significant differentiator.
• Physician and Patient Education: Ongoing efforts to educate healthcare providers and patients about orexin antagonism contribute to adoption.

Market Challenges:

• Competition: The insomnia market is crowded with established generics and branded drugs, including newer entrants like daridorexant.
• Pricing and Reimbursement: The cost of Belsomra relative to generics and older drugs can impact its accessibility and prescription rates. Payer restrictions and prior authorization requirements can limit use.
• Efficacy Perception: While effective, Belsomra's onset of action and duration of effect may be perceived differently by patients and physicians compared to faster-acting agents.
• Generic Entry: As patent exclusivity wanes, the threat of generic competition will increase, significantly impacting sales.
• Side Effects: Despite a generally favorable profile, Belsomra has potential side effects, including somnolence, headache, and dizziness, which can affect adherence.

What is the projected financial trajectory for Belsomra post-patent expiration?

The primary U.S. patent for Belsomra (U.S. Patent No. 7,314,890) expires on January 1, 2027. Following this expiration, generic versions of suvorexant are expected to enter the market.

Historically, the introduction of generics leads to a substantial decrease in the revenue of the branded drug. This decline is driven by:

• Price Erosion: Generic drugs are priced significantly lower than branded counterparts, forcing price reductions for the originator product.
• Market Share Shift: Healthcare providers and patients often switch to more affordable generic options.
• Increased Competition: Multiple generic manufacturers entering the market further intensifies price competition.

Merck's revenue from Belsomra is anticipated to decline sharply after January 2027. While some market share may be retained due to physician preference, brand loyalty, or specific formulary placements, the overall financial contribution is expected to diminish considerably. Merck's focus will likely shift to managing the decline in Belsomra sales and prioritizing other revenue-generating assets in its portfolio. The company may also explore lifecycle management strategies, although the impact of such strategies post-major patent expiry is often limited.

The development of secondary patents, such as those covering polymorphs expiring in 2031, could offer some residual protection against certain generic formulations or manufacturing processes. However, the core composition of matter patent expiration remains the most significant factor influencing the drug's financial trajectory.

Key Takeaways

Belsomra's market trajectory is characterized by its novel mechanism of action as a dual orexin receptor antagonist, offering a differentiated profile in the competitive insomnia market. Financial performance has shown steady growth post-launch, peaking in 2020, but has seen a slight decline in recent years. Key drivers include the unmet need for insomnia treatment and its favorable safety profile compared to older hypnotics. Challenges stem from intense competition, pricing pressures, and the impending threat of generic entry. The expiration of its primary U.S. patent in January 2027 is projected to lead to a significant revenue decline due to generic substitution.

FAQs

1. When did Belsomra receive FDA approval? Belsomra received FDA approval on August 8, 2014.

2. What is the primary mechanism by which Belsomra works? Belsomra is a dual orexin receptor antagonist that blocks the binding of orexin neuropeptides, thereby reducing wakefulness and promoting sleep.

3. Which is the main U.S. patent protecting Belsomra and when does it expire? The main U.S. patent protecting Belsomra is U.S. Patent No. 7,314,890, which expires on January 1, 2027.

4. What is the competitive market for Belsomra? Belsomra competes with benzodiazepines, Z-drugs, melatonin receptor agonists, off-label antidepressants, and other orexin receptor antagonists.

5. What financial impact is expected after Belsomra's primary patent expires? Following the expiration of its primary patent in January 2027, Belsomra is expected to experience a significant decline in revenue due to the introduction of generic suvorexant.

Citations

[1] United States Patent and Trademark Office (USPTO). (n.d.). Patent Search. Retrieved from https://patft.uspto.gov/ (Specific patent numbers searched: 7,314,890; 9,205,041)

[2] Merck & Co., Inc. (2016). Form 10-K for the fiscal year ended December 31, 2015. U.S. Securities and Exchange Commission.

[3] Merck & Co., Inc. (2017). Form 10-K for the fiscal year ended December 31, 2016. U.S. Securities and Exchange Commission.

[4] Merck & Co., Inc. (2018). Form 10-K for the fiscal year ended December 31, 2017. U.S. Securities and Exchange Commission.

[5] Merck & Co., Inc. (2019). Form 10-K for the fiscal year ended December 31, 2018. U.S. Securities and Exchange Commission.

[6] Merck & Co., Inc. (2020). Form 10-K for the fiscal year ended December 31, 2019. U.S. Securities and Exchange Commission.

[7] Merck & Co., Inc. (2021). Form 10-K for the fiscal year ended December 31, 2020. U.S. Securities and Exchange Commission.

[8] Merck & Co., Inc. (2022). Form 10-K for the fiscal year ended December 31, 2021. U.S. Securities and Exchange Commission.

[9] Merck & Co., Inc. (2023). Form 10-K for the fiscal year ended December 31, 2022. U.S. Securities and Exchange Commission.

[10] Merck & Co., Inc. (2024). Form 10-K for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.